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Dummary
Recombinant adenoviral vectors (Ad) liave been ernployed for clinical
gene tirerapy applications for cancer based on their unparalleled ability to
accomplish in vi.'o gene transfer. Despite this capacity, current generation
Ad are not fully suited for this application. From a conceptual standpoint,
tumor selective targeting would enhance the specific delivery of anti-cancer
genes to disease sites, thus improving the overall therapeutic index of any
such approach. From a practical standpoint, tumors have been noted to
exhibit a profound deficiency of the primary Ad receptor, coxsackie-and-
adenovirus receptor (CAR). Both of these considerations predicate the need
to alter the tropism Ad to address these points. In the first instance, the
ability to target Ad to cancer-specify markers would be suggested. ln the
second instance, the ability to route the virus via non-CAR cellular pathways
isrequired. Both of these key issues have been addressed in this thesis. We
have sought to achieve these linked goals via a variety of strategies for Ad
tropism modification. The fullest realization of the practical benef-rts of such
efforts may ultimately be realized via genetic capsid modrfication
approaches, which are the main focus of this thesis work. In the aggregate.
we have established herein key principles rvith respect o adenovirus biology
relevant to adenovirus vector util ity. These principles have direct
consequence for curent human clinical gene therapy approaches for cancer
and point clearly to the direction in which current vectorology efforts most
focus to realize the full potential ofcancer gene therapy.
In Chapter II of thesis we endeavored to alter the tropism of Ad via zr
strategy of capsid protein chimerism. Specifically, we configured the flber
knob of the Ad serotype 3 vims within the context of an Ad serotype 5
vector. This study established that major capsid protein engineering could
be accomplished by genetic techniques. In addition, we showed that the
fiber knob was the major dictate of vector tropism; mosaic Ad contarning
only the 3 knob exhibited a tropism pattern similar to an Ad 3 r,irus. Of
note, this strategy allowed routing of the derived mosaic vector to non-CAR
pathways. This study represented the first ever alteration of Ad tropism
based on genetic capsid modiflcation. Fufiher, these findings were the llrst
to establish the concept of "CAR-independent" gene delivery achievable via
tropism alterations. Our subsequent studies have shown that the receptor of
the serotype 3 Ad can be exploited for gene delivery in the context of tumor
targets characterized by CAR deficiency. Dramatic augmentatioir in gene
h'ansfer efficiency were obtainable in these instances. On the basis of these
studies we thus understand that: (1)it is possible to alter Ad tropism via
genetic capsid rnodification (2) such rnodifications allowed CAR-
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independent gene delivery (3) CAR-independent infection allowed dramatic
efficiency enhancemc-nt of gene delivery in the context of CAR-deficient
tumor targets.
In Chapter III we explored the possibility of more defined genetic capsid
modifications consistent with the possibility of vector targeting. To this end
we sought to identify locales within the Ad capsid capable of incorporation
of heterologous targeting motifs. Based on available crystal structure
analvsis, we proposecl the HI loop of the fiber knob as a candidate site which
would embody the requirements for effective presentation of a targeting
motif-. Key to realization of these requirements would be the ability to retain
the structural facets of the fibel in a trimeric context ancl the presentation of
the incorporated ligand on an exposed surface locale. To this end we
confi-eured a FLAG epitope of the HI loop in the context of recombinant
fiber and intact viral vector. Analysis of these substrates demonstrated that
peptide incorporation at the Hl loop did not abrogate fiber trimerizatiou
and/or parlicle assernbly. Fufther, the peptide localized in this site presented
a surface localization, potentially available for target cell receptor
interaction. These key studies thus established a potential link between
target definition technologies, such as phage biopanning of peptides/scFv,
and vector targeting technologies. Subsequent work allowed the
incorporation of the tumor targeting peptide RGD4C of the HI loop locale.
This modiflcation allowed the achievement of CAR-independent infection
with dramatic efficiency enhancements of gene transfer to CAR-deficient
targets. This specific rnodification allolved improvements of vector potency
in the context of both Ad vectors and replicative adenoviral agents designed
fbr tLunor therapy (3,4). ln addition. this particular targeting peptide
provides a level of tnre tumor targeting in selected instances. On this basis,
Hl loop modified Ad are curently being advanced into human clinical trials
for cancer. These trials represent he flrst ever employment of tropism
modified viral vectors in the history of human gene therapy.
In Chapter lV we endeavored to establish the feasibility of true tumor
targeting via tropism nrodification of Ad. To this end, we re-targeted Ad
employing a bispecific adapter consisting of an anti-fiber knob mAb
conjugated to an mAb for the tumor specific marker EpCAM. In these
studies we could demonstrate that specitic gene transfer to target cells was
achieved via the targeted EpCAM pathrvay. Of note, the levels of retargeted
Ad mediated gene transfer closely paralleled the levels of EpCAM
characterizing each ol' the tested tumor targets. These findings clearly
established that true tumor-specific targeting was acirievable l' ia tropisnr-
modification of Ad. These studres were extended to the context of primary
clinical material directly obtained from cancer patients. In these studies, the
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EpCAM targeted Ad dernonstrated augmented gene transf-er to colon cancer
specimens compared to unrnodified Ad. These findings highlighted the
concept that tumor targeted Ad may achieve gene transfer efficiency
enhancements via the achievement of CAR-independent infection, over-and-
above specificity gains. Of further note, the targeted vector exhibit a
dramatic enhancement in targeting index compared to notr-ntodifled Ad
when evaluated in the context of primary tumor versus primary ttormal tissue
employing antibody retargeting moieties for the achievement of specific
tar-eeting. In addition, the dramatic improvement in targetin-e index obtained
in studies of clinical specirnens highlighted the shoficomings of current Ad
vectors employed in clinical trials by suggesting the potential gains in
therapeutic index obtainable via the approach. Of special note, tlre
successful exploitation of available anti-tumor antibodies suggested the
possibility of broader utility of these agents" or their derivatives, fbr tropism
modification of Ad designed to achieve tllmor targeting.
In Chapter V we sought to extend our findings of the previous study by
improving the technical means to exploit anti-tumor antibodies for Ad
tropism modification. ln this regard, earlier reports of Ad retargeting had
exploited bispecific retargeting adapters to cross-link Ad to non-CAR
receptors. These molecular species were, in the main, derived from
chemical conjugates of anti-fiber knob mAb and a cellular ligand or anti-
receptor mAb. This approach was limited by the heterogenous trature of
such preparations deriving from these methods. Of note, these technical
limits represented legitirnate barriers for clinical translation of antibody
retargeted Ad. On this basis we endeavored to derive the benefits of tumor
selective targeting provided by anti-cancer mAbs in a manner which
circumvents the inherial limits noted above. To this end we derived
bispecific single chain antibodies to serve as bispecific retargeting adapters
for Ad tropism modification. A single chain antibody (scFv) directed
against he fiber knob was genetically fused to au scFv against the tumor
marker EGF-R. Our studies demonstrated that the designed bispecific
antibody could be expressed in mammalian cell systems and could be
pr"rrified to hornogeneity via an incorporated tag system. Of note, the
bispecific antibody functioned successfully as a bispecific retargeting
adapter, allowing tumor selective gene delivery specifically to cells
erpressing EGF-R. These studies thus establishecl a practical ntearls to
exploit scFv for Ad retargeting. This represents a highly relevant
consideration in the context of the available anti-tumor scFv which can
presently be exploited in this fashion. Fufiher, the functional util ity of scFv
for Ad retargeting to tumor establishes the biologic basis of futrtre uses
which might be based on direct incorporatiotr of scFv into the Ad capsid.
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ln Chapter VI we sought to define additional methods for genetic capsid
incorporation of targeting ligands commensurate with our tumor targeting
goals. In this regard, detrned fiber locales for incorporatiort of targeting
ligands were all limited by the structural constraints imposed by the fiber
knob domain. On this basis, only srnall peptide ligands were of potential
util ity. Given the limited available repertoire of peptide ligands, and in
consideratiorr of the availability of specific anti-tumor scFv, we sought to
define a capsid locale for ligand incorporation potentially free of knob-
imposed structural constraints. To this end rve advanced an approach based
on substitution of fiber shaft and knob with an alternate protein which would
provide a trimerizated structure to compensate for loss of the fiber domains
associated with this key structural aspect. We showed that chimeric fiber
molecules could be designed, and derived, which contained the
bacteriophage T4 Pol protein fibritin as a fiber knob/shaft substitute.
Recombinant forms of these molecules trimerized and presented ligand in a
surface accessible lnanner. Imporlantly, viable virus cor"rld be rescued which
incorporated the chimeric fiber replacement protein. Furlher. such virions
could fr.rnction as vectors with successful gene transfer noted to target cell
accornplished in a targeted manner based on Ad-incorporated ligands. The
main intent of this work was to establish the feasibility of fiber replacement
as a Ineans to aclrieve capsid incorporation of desirable targeting ligands,
such as scFv. Established feasibilities in this study provided a practical
system to evaluate this concept. In further work we have shown that the
fiber replacement approach is indeed compatible with capsid incorporation
of larger/more complex targeting ligands than possrble in the context of knob
structure imposed constraints. Current work is focused upon demonstrating
the functionality of anti-tumor scFv configured into the Ad capsid via the
fibritin approach.
In Chapter VII we sought to identi!'additional capsid sites compatible
with incorporation of heterologeous targeting motifs. ln this regard,
preceding work had focr-rsed largely on the major capsid proteins fiber.
hexon and penton to achieve these ends. Irr intrinsic lirnits of these locales
restricted the type and range of targeting ligands exploitable and thus led us
to explore a novel locale. The plX protein is one of the so called "cement
proteins" of the capsid and is thought to function as a stabilizer for intra-
hexon assembly. Based on the recognition that its C temrinus w'as in an
ectodomain locale with respect o the capsid, we explored it util ity as a site
fbr incorporation of targeting ligands. Studies employing tag peptides
established that heterologeous peptide could be incorporated at pIX without
any deleterious eff-ect on viral rescue. In addition, C terminus tag was
localized on the virion ecotodomain. accessible for surface-to-surface
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interactions. lncorporation of small peptide ligands at the C tenninus of plX
allowed altered Ad tropism with the achievenrent of CAR-independent gene
delivery. These studies thus established the podtential util ity of plX as a
candidate locale for ligancl incorporation of the context of genetic capisd
rurodification strategies for altering Ad tropism. We have ertended the
stuclies described in this chapter by evaluating the feasibility of scFv
incorporation of the C terminus of plX. These data have established that
scFv can be incorporated at this locale with the rescue of viable virus.
Fufther, the incorporated scFv contribr-rted to Ad tropism, indicating, scFv
function in the context of capsid incorporation. This represents the first such
demonstration of genetic scFv incorporation within the Ad capsid rvith
altered vector tropism and represents a field milestone.
In Chapter VIII we explored the initial basis of a novel targeting paradigm
based on the exploitation of multiple tropism alterations within a targeted Ad
vector. Such a strategy of "complex rnosaicism" would offer theoretic
advantages - 1) distinct infectivity enhancement modifications could operate
additively, or synergistically, to maximize vector gene transfer potency 2)
distinct argeting motifs could operate in a cross-supportive manner to of-fer
more precise target cell selectrvity based on highly individualized profiling.
The starting point for realization of these ends is the demonstration that an
Ad5 vector can incorporate more than one genetic capsid modification which
embodies a tropism modification principal. To this end, we sought o derive
an Ad which was chimeric with respect o the fiber knob (serotype 3
substituted for native 5) and containing a C terminus fiber addition. Such a
complex mosaic Ad was designed and successfully rescued. Of note, both
distinct capsid modification rvere capable of functional operation in the
context of the presence of the other. 'Ihis key first step has thus established
the practical basis of deriving complex rnosaic Ad. This study represents the
first ever demonstration of this concept. The mc'aus to incorporate multiple,
and distinct, targeting motifs within a single vector particle will allow study
of vector gains with respect o gene transfer efficiency and target cell
specifically. Both of these considerations are of key relevance in
consideration ofthe requirements ofcancer gene therapy approaches.
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